Do you want to read an article? Please log in or register.
Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy
Retinal Diseases
Related content
COMMENTED
Retinal Diseases
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience
Br J Ophthalmol.
Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, Rachitskaya AV, Kaiser PK, Schachat AP, Srivastava SK, Sharma S, Singh RP
doi: 10.1136/bjophthalmol-2019-314047.
COMMENTED
Retinal Diseases
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
★ 3
Recommended by
Dr Katarzyna Konieczka, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Lancet.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators
doi: 10.1016/S0140-6736(19)32981-2.
Retinal Diseases
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial
Ophthalmology.
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF
doi: 10.1016/j.ophtha.
Retinal Diseases
Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy
J Clin Med.
Borrelli E, Zuccaro B, Zucchiatti I, Parravano M, Querques L, Costanzo E, Sacconi R, Prascina F, Scarinci F, Bandello F, Querques G
doi: 10.3390/jcm8091271.Visit the original publication at ncbi.nlm.nih.gov
Retinal Diseases
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy
Ophthalmology.
Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA
doi: 10.1016/j.ophtha.2018.12.048.
Retinal Diseases
GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY
Retina.
Mohabati D, Schellevis RL, van Dijk EHC, Altay L, Fauser S, Hoyng CB, De Jong EK, Boon CJF, Yzer S
doi: 10.1097/IAE.
Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy
JAMA Ophthalmol.
van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJ, de Jong EK
doi: 10.1001/
Further Publications
Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial
Am J Ophthalmol
van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF
doi: 10.1016/j.ajo.2021.06.020
COMMENTED
Retinal Diseases
Central serous chorioretinopathy: Towards an evidence-based treatment guideline
Prog Retin Eye Res.
van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF
doi: 10.1016/